PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM
Nov 1, 2008, 00:00 AM
10.1016/S1098-3015(10)66603-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)66603-X/fulltext
Section Title :
Section Order :
438
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66603-X&doi=10.1016/S1098-3015(10)66603-X